COVID-19 Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight's "COVID-19 Pipeline Insight" report provides comprehensive insights about key companies and pipeline drugs in the COVID-19 pipeline landscapes. It comprises COVID-19 pipeline drug profiles, including clinical and non-clinical stage products. It also includes the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive COVID-19 pipeline products.

To Know about COVID-19 Pipeline Report: https://www.delveinsight.com/report-store/covid-19-coronavirus-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key takeaways of the COVID-19 Pipeline Report
1. Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as, Amgen, Corvus Pharmaceuticals, Fulcrum Therapeutics, Synairgen Research. Revive Therapeutics, Novavax, Valneva, etc., are developing therapies for the treatment of COVID-19.
2. Emerging therapies such as Otezla (Apremilast), CPI-006, Losmapimod, SNG001 (Interferon beta-1a), Bucillamine, NVX-CoV2373, VLA2001, are expected to have a significant impact on the COVID-19 market in the coming years.

Get an overview of pipeline landscape @ https://www.delveinsight.com/report-store/covid-19-coronavirus-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

COVID-19 Overview
COVID-19 is an infectious disease caused by a newly discovered coronavirus, i.e., SARS-CoV-2. It spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. CoVs are enveloped, positive-stranded RNA viruses with nucleocapsids. The pathogenic mechanism which causes pneumonia seems to be complex

COVID-19 Therapeutics Assessments
1. Otezla (Apremilast): Amgen
2. CPI-006: Corvus Pharmaceuticals
3. Losmapimod: Fulcrum Therapeutics
4. SNG001 (Interferon beta-1a): Synairgen Research
5. Bucillamine: Revive Therapeutics
6. NVX-CoV2373: Novavax
7. VLA2001: Valneva

For further information, refer to the detailed report @ https://www.delveinsight.com/report-store/covid-19-coronavirus-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of COVID-19 Pipeline Drug Insight
1. Coverage: Global
2. Major Players: Amgen, Corvus Pharmaceuticals, Fulcrum Therapeutics, Synairgen Research. Revive Therapeutics, Novavax, Valneva, and others.
3. Pipeline Therapies: Otezla (Apremilast), CPI-006, Losmapimod, SNG001 (Interferon beta-1a), Bucillamine, NVX-CoV2373, VLA2001, and others.

Table of Contents:
1. Report Introduction
2. COVID-19(CoronaVirus) - Disease Overview
3. Pipeline Outlook
4. Comparative Analysis
5. COVID-19(CoronaVirus) Therapeutic Products in Clinical Stage
6. COVID-19(CoronaVirus) Therapeutic Products in Non-clinical Stage
7. Therapeutic Pipeline Analysis
8. Inactive Pipeline Products
9. Appendix
10. Report Methodology
11. Consulting Services
12. Disclaimer
13. About DelveInsight

Get a customized pipeline report @ https://www.delveinsight.com/report-store/covid-19-coronavirus-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Contact Us:
Kritika Rehani
krehani@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.